Mechanisms underlying estrogen protection against paclitaxel-induced peripheral neuropathy: Modulation of upstream and downstream signals of high mobility group box 1
Maho Tsubota, Ayano Kanto, Shiori Hiramoto, Fumiko Sekiguchi, Yasuko Tomono, Masahiro Nishibori, Atsufumi Kawabata · FENS Forum 2024
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reactions in chemotherapy with cytotoxic anticancer agents. We have demonstrated that CIPN caused by paclitaxel involves high mobility group box 1 (HMGB1), a nuclear protein, derived from macrophages (Mφ) in laboratory animals (Neuropharmacology 141, 201, 2018), and that postmenopausal estrogen decline aggravates CIPN in patients undergoing paclitaxel-based chemotherapy (J Pharmacol Sci 146, 49, 2021). In this study, we analyzed estrogen modulation of upstream and downstream mechanisms of HMGB1. Female mice were subje
ePoster · Neuroscience